The proposed guideline will replace ‘points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome CPMP/EWP/785/97’. Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder in which abdominal discomfort or pain is associated with changes in bowel habits, stool consistency and other features of disordered defecation.

Consultation start date 08/06/2012
Consultation end date 31/08/2012
Email address for submissions


Posted on the EMA webiste, 8 June 2012